ImmunityBio clinical trials we track

Check company identity source

Phase 3 3 trials

Phase 2 / 3 2 trials

Phase 2 19 trials

TrialDrugs studiedStatusPrimary completion
Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaNCT07125872CD19 t-haNK- IV AdministrationRecruiting2027-05-25Estimated
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerNCT06710288Gemcitabine, M-CENK, N-803Recruiting2027-05Estimated
A Study to Examine Anktiva for the Treatment of COVID-19.NCT07123727AnktivaRecruiting2027-03Estimated
A Study to Assess Anktiva in Patients With Long Covid-19.NCT07108036N-803 (IL-15 Superagonist)Recruiting2026-10Estimated
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNCT07628062Cisplatin, De-Intensified IMRT, Nab-Paclitaxel, Nogapendekin Alfa Inbakicept (NAI) and 2 moreNot yet recruiting2030-12-31Estimated
NAI Plus Standard of Care Compared To SOC Alone Plus Standard of Care in Critically Ill Adults With SepsisNCT07783789Nogapendekin alfa inbakicept (NAI)Not yet recruiting2028-05-12Estimated
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNCT07477366CD19 t-haNK- IV Administration, N-803, rituximabNot yet recruiting2027-12Estimated
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNCT06829823N-803 and BCG, N-803 and GemcitabineNot yet recruiting2026-11Estimated
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaNCT06061809Bevacizumab, N-803, PD-L1 t-haNK, Tumor Treating Fields (TTFields, 200 kHz)Active not recruiting2029-12-31Estimated
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667N-803 + Atezolizumab, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab, N-803 + Avelumab + PD-L1 t-haNK and 8 moreActive not recruiting2029-08-31Estimated
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT043903995-Fluorouracil, Aldoxorubicin HCl, Cyclophosphamide, Gemcitabine and 6 moreActive not recruiting2025-10-13Actual
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung CancerNCT02200757Aldoxorubicin, TopotecanCompleted2017-05-15Actual
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With GlioblastomaNCT02014844250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicinCompleted2016-12Actual
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's SarcomaNCT02029430100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin, 50 mg/m2 aldoxorubicinCompleted2016-04-25Actual
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue SarcomaNCT01514188Doxorubicin, INNO-206Completed2014-04-09Actual
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic CancerNCT01580397INNO-206Completed2013-05-13Actual
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyNCT03853317Avelumab, N-803, haNK™Terminated2021-09-29Actual
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)NCT02465957aNK (NK-92), aNK (NK-92) + N-803Terminated2018-03-19Actual
NAI for Sepsis With Persistent LymphopeniaNCT07578558Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC)Withdrawn2027-08-03Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: 28-day all-cause mortality rate Description: Proportion of participants who die from any cause by Day 28 after the first dose of study treatment. Time frame: From Day 1 (first NAI dose) through Day 28. After: Measure: 28-day all-cause mortality rate Description: Proportion of participants who die from any cause by Day 28 after the first dose of study treatment. Time frame: From Day 1 (first dose of study treatment) through Day 28.

Check registry source
NAI for Sepsis With Persistent Lymphopenia

NCT07578558 · ImmunityBio, Inc.

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 50 participants (planned). After: 0 participants (actual).

Recruitment status changed

Before: Not yet recruiting. After: Withdrawn.

Check registry source

· 1 field changed

Planned enrollment increased by 47 participants

Before: 460 participants (planned). After: 507 participants (planned).

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 1538 participants (planned). After: 102 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 31 Oct 2026. After: 13 Oct 2025.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective Response Rate Measure: Prolongation of Overall Survival (OS) with NAI Therapy by ALC Response. After: Measure: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. Measure: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ.

Check registry source